For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome
Synthetic peptide corresponding to Human BCMA (C terminal).
(Peptide available as
Members in the TNF superfamily regulate immune responses and induce apoptosis. Two novel members in the TNF family were recently identified and designated BAFF/BLyS/TALL1/THANK/zTNF4 and April/TALL2, respectively. BAFF was characterized as a B cell activator since it induced B cell proliferation and immunoglobulin secretion. April regulates immunological and non immunological cell growth. Three receptors, BCMA (for B cell maturation protein), TACI, and BAFFR, for BAFF were recently identified. BCMA, like TACI, binds BAFF and April. BAFF and its receptors induce B cell development and survival, activate NF-kappaB and c-jun N-terminal kinase, and are involved in B cell associated autoimmune diseases.
Our Abpromise guarantee covers the use of ab5972 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ICC/IF||Use a concentration of 20 µg/ml.|
|IHC-P||Use a concentration of 10 µg/ml.|
|WB||Use a concentration of 2 - 5 µg/ml. Predicted molecular weight: 20 kDa.Can be blocked with BCMA peptide (ab6087).|
ab5972 at 10µg/ml staining BCMA in human spleen cells by IHC
Immunohistochemistry of BCMA in human spleen tissue with BCMA antibody at 5 µg/ml.
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"